Recurrent Malignant Gliomas

Overview

Journal Semin Radiat Oncol

Specialties Oncology
Radiology

Date 2014 Sep 16

PMID 25219814

Citations 32

Authors

John P Kirkpatrick

John H Sampson

Affiliations

Soon will be listed here.

Abstract

In almost all patients, malignant glioma recurs following initial treatment with maximal safe resection, conformal radiotherapy, and temozolomide. This review describes the many options for treatment of recurrent malignant gliomas, including reoperation, alternating electric field therapy, chemotherapy, stereotactic radiotherapy or radiosurgery, or some combination of these modalities, presenting the evidence for each approach. No standard of care has been established, though the antiangiogenic agent, bevacizumab; stereotactic radiotherapy or radiosurgery; and, perhaps, combined treatment with these 2 modalities appear to offer modest benefits over other approaches. Clearly, randomized trials of these options would be advantageous, and novel, more efficacious approaches are urgently needed.

Citing Articles

Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma.

Margulies A, Sahki N, Rech F, Vogin G, Blonski M, Peiffert D Radiat Oncol. 2025; 20(1):28.

PMID: 40022217 PMC: 11871646. DOI: 10.1186/s13014-025-02611-0.

Hyperbaric oxygen therapy enhances restoration of physical functional in patients with recurrent glioma: A case report.

Cai T, Jin T, Guan Y, Zou W, Wang X, Zhu Y Oncol Lett. 2024; 28(6):583.

PMID: 39421317 PMC: 11484218. DOI: 10.3892/ol.2024.14716.

Intraoperative and postoperative complications for repeat high-grade glioma resections with concurrent chemotherapy: patient series.

Ong K, Hounjet C, Makarenko S J Neurosurg Case Lessons. 2023; 6(16).

PMID: 37870760 PMC: 10584083. DOI: 10.3171/CASE23341.

Radiomics: The New Promise for Differentiating Progression, Recurrence, Pseudoprogression, and Radionecrosis in Glioma and Glioblastoma Multiforme.

Alizadeh M, Lomer N, Azami M, Khalafi M, Shobeiri P, Arab Bafrani M Cancers (Basel). 2023; 15(18).

PMID: 37760399 PMC: 10526457. DOI: 10.3390/cancers15184429.

Intraoperative ultrasound in recurrent gliomas surgery: Impact on residual tumor volume and patient outcomes.

Wang M, Yu J, Zhang J, Pan Z, Chen J Front Oncol. 2023; 13:1161496.

PMID: 37035181 PMC: 10076842. DOI: 10.3389/fonc.2023.1161496.

References

Cabrera A, Cuneo K, Desjardins A, Sampson J, McSherry F, Herndon 2nd J . Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys. 2013; 86(5):873-9. DOI: 10.1016/j.ijrobp.2013.04.029. View

De Bonis P, Fiorentino A, Anile C, Balducci M, Pompucci A, Chiesa S . The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin Neurol Neurosurg. 2012; 115(7):883-6. DOI: 10.1016/j.clineuro.2012.08.030. View

Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Stefano D . Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol. 2012; 111(2):187-94. DOI: 10.1007/s11060-012-0999-9. View

Nghiemphu P, Liu W, Lee Y, Than T, Graham C, Lai A . Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009; 72(14):1217-22. PMC: 2677488. DOI: 10.1212/01.wnl.0000345668.03039.90. View

Hochberg F, Pruitt A . Assumptions in the radiotherapy of glioblastoma. Neurology. 1980; 30(9):907-11. DOI: 10.1212/wnl.30.9.907. View

Kreisl T, Smith P, Sul J, Salgado C, Iwamoto F, Shih J . Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2012; 111(1):41-8. DOI: 10.1007/s11060-012-0988-z. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Pinsker M, Lumenta C . Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir. 2002; 62(2):43-7. DOI: 10.1055/s-2002-19477. View

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

10.

Larson D, Prados M, Lamborn K, Smith V, Sneed P, Chang S . Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2002; 54(5):1397-404. DOI: 10.1016/s0360-3016(02)03743-4. View

11.

Shrieve D, Alexander 3rd E, Wen P, Fine H, Kooy H, Black P . Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995; 36(2):275-82; discussion 282-4. DOI: 10.1227/00006123-199502000-00006. View

12.

Kirkpatrick J, Brenner D, Orton C . Point/Counterpoint. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Med Phys. 2009; 36(8):3381-4. DOI: 10.1118/1.3157095. View

13.

Gorlia T, Stupp R, Brandes A, Rampling R, Fumoleau P, Dittrich C . New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012; 48(8):1176-84. DOI: 10.1016/j.ejca.2012.02.004. View

14.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

15.

Levin V, Bidaut L, Hou P, Kumar A, Wefel J, Bekele B . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010; 79(5):1487-95. PMC: 2908725. DOI: 10.1016/j.ijrobp.2009.12.061. View

16.

Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M . Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 2013; 119(15):2747-53. PMC: 4001735. DOI: 10.1002/cncr.28031. View

17.

Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, Dirican B . Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: a single center experience. Vojnosanit Pregl. 2011; 68(11):961-6. DOI: 10.2298/vsp1111961s. View

18.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

19.

Balmaceda C, Peereboom D, Pannullo S, Cheung Y, Fisher P, Alavi J . Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008; 112(5):1139-46. DOI: 10.1002/cncr.23167. View

20.

Cho K, Hall W, Gerbi B, Higgins P, McGuire W, Clark H . Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999; 45(5):1133-41. DOI: 10.1016/s0360-3016(99)00336-3. View